Evidence map›Paper›PMID 32980648›Full record

ArticleBreast (Edinburgh, Scotland)2020

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK).

Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh and 7 more

Open access · goldAbstract readEvaluation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Min Ho ParkDepartment of Surgery, Chonnam National University Medical School, Gwangju, South Korea.
Soo Jung LeeDepartment of Surgery, Yeungnam University College of Medicine, Daegu, South Korea.
Woo Chul NohDepartment of Surgery, Korea Cancer Center Hospital, Seoul, South Korea.
Chang Wan JeonDepartment of Surgery, Kosin University Gospel Hospital, Seoul, South Korea.
Seok Won LeeDepartment of Surgery, Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
Gil Soo SonDepartment of Surgery, Korea University Ansan Hospital, Ansan, South Korea.
Byung-In MoonDepartment of Surgery, Ewha Women's University School of Medicine, Seoul, South Korea.
Jin Sun LeeDepartment of Surgery, Chungnam National University Hospital, Daejeon, South Korea.
Sung Soo KangDepartment of Surgery, CHA University Ilsan Medical Center, Goyang, South Korea.
Young Jin SuhDepartment of Surgery, Catholic University of Korea, St. Vincent's Hospital, Suwon, South Korea.
Geumhee GwakDepartment of Surgery, Inje University Sanggye Paik Hospital, Seoul, South Korea.
Tae Hyun KimDepartment of Surgery, Inje University Busan Paik Hospital, Busan, South Korea.
Young Bum YooDepartment of Surgery, Konkuk University Medical Center, Cheongju, South Korea.
Hyun-Ah KimDepartment of Surgery, Korea Cancer Center Hospital, Seoul, South Korea.
Min Young KimMedical Department, Eisai Korea Inc., Seoul, South Korea.
Ju Yeon KimMedical Department, Eisai Korea Inc., Seoul, South Korea.
Joon JeongDepartment of Surgery, Gangnam Severance Hospital Yonsei University, Seoul, South Korea. Electronic address: gsjjoon@yuhs.ac.
Eisai (South Korea) · KRPusan National University Hospital · KRBaewha Women's University · KRCHA University · KRChonnam National University Hospital · KRChungnam National University Hospital · KRInje University Busan Paik Hospital · KRInje University Sanggye Paik Hospital · KRKonkuk University Medical Center · KRKorea University · KRKosin University Gospel Hospital · KRThe Catholic University of Korea St. Vincent's Hospital · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeApproval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study.

methodsPatients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m

resultsThe safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common.

conclusionReal-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified.

Indexed as

AdultAntineoplastic AgentsBreast NeoplasmsFemaleFuransHumansKetonesMiddle AgedPolyether PolyketidesProgression-Free SurvivalRepublic of KoreaRetrospective StudiesTreatment OutcomeAntineoplastic AgentseribulinFuransKetonesPolyether PolyketidesBreast cancerEribulin mesylateKorean patientsRetrospective study

Identifiers

PMID32980648
PMCPMC7519365
OpenAlexW3087590574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.